EPAM three-lens brief
Evidence-based stock research on EPAM. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 9% of its 52-week range — deep in the lower band.
- Trading at 9% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 15.6pp over 30 days.
- Analyst mean target $140.53 — 63% above current (17 analysts).
- Earnings scheduled 2026-08-06.
EPAM closed at $86.23 (-1.21%) as of 2026-07-10. Market cap: $4.51B. P/E (trailing) 12.2. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $140.53 — 63% above current (17 analysts).. Concerns: trading at 9% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $1.40B, net income $82.52M, free cash flow $692.90M. Watching for: 2026-08-06 earnings release (26 days out).
Why three lenses on EPAM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine EPAMacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/EPAM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath EPAM brief"></iframe>